Astria Therapeutics, Inc. has 14 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Glazer Capital, LLC | 6.61% | 3,776,154 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| Fairmount Funds Management LLC | 4% | 2,377,049 | SCHEDULE 13G/A, 2025-10-15 | 2025-10-14 |
| Fmr LLC | 2.2% | 1,251,766 | SCHEDULE 13G/A, 2025-11-07 | 2025-10-31 |
| Millennium Management LLC | 0.4% | 222,101 | SCHEDULE 13G/A, 2025-10-20 | 2025-10-14 |
| RA Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Perceptive Advisors LLC | 0% | 0 | SCHEDULE 13D/A, 2026-02-09 | 2026-01-26 |
| Magnetar Financial LLC | 0% | 0 | SCHEDULE 13D/A, 2026-01-28 | 2026-01-26 |
| Vestal Point Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| ForGrowth III PA B.V. | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-10-16 |
Purpose of Transaction (Item 4)
Perceptive Advisors LLC
The Reporting Persons' beneficial ownership in the Issuer changed as a result of the consummation of the previously announced acquisition of the Issuer by BioCryst pursuant to the Merger Agreement . The Merger was completed on January 23, 2026, and the Issuer ceased to exist as a separate entity. As a result of the merger, the Reporting Persons no longer beneficially owns any shares of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-02-09
Magnetar Financial LLC
Since the filing of the Schedule 13D on October 24, 2025, on January 23, 2026, the Issuer consummated a merger (the "Merger") pursuant to which each issued and outstanding Share was cancelled and converted into the right to receive $8.55 in cash, without interest. In connection with the Merger, the Reporting Persons' 3,431,007 Shares, which consisted of 1,560,502 Shares sold for the benefit of PRA Master Fund; 804,159 Shares sold for the benefit of Systematic Master Fund; 221,576 Shares sold for the benefit of the Relative Value Master Fund and 844,770 Shares sold for the benefit of two Managed Accounts, were cancelled and converted into the right to receive $8.55 in cash, without interest.Item 4 of the SCHEDULE 13D/A filed 2026-01-28
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | RA Capital Management, L.P. | 0% | SCHEDULE 13G/A |
| 2025-10-15 | Fairmount Funds Management LLC | 4% | SCHEDULE 13G/A |
| 2025-10-16 | Perceptive Advisors LLC | 11.5% | SCHEDULE 13D/A |
| 2025-10-20 | Millennium Management LLC | 0.4% | SCHEDULE 13G/A |
| 2025-10-24 | Magnetar Financial LLC | 5.87% | SCHEDULE 13D |
| 2025-11-05 | Fmr LLC | 9.1% | SCHEDULE 13G/A |
| 2025-11-07 | Fmr LLC | 2.2% | SCHEDULE 13G/A |
| 2025-11-14 | Vestal Point Capital, LP | 8.8% | SCHEDULE 13G/A |
| 2025-11-14 | ForGrowth III PA B.V. | 0% | SCHEDULE 13G/A |
| 2025-12-10 | Glazer Capital, LLC | 5.53% | SCHEDULE 13G |
| 2026-01-28 | Magnetar Financial LLC | 0% | SCHEDULE 13D/A |
| 2026-02-09 | Perceptive Advisors LLC | 0% | SCHEDULE 13D/A |
| 2026-02-12 | Glazer Capital, LLC | 6.61% | SCHEDULE 13G/A |
| 2026-02-17 | Vestal Point Capital, LP | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Astria Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.